AKT3 and hemimegalencephaly: ENS arises from activating mutations in PIK3CA or AKT3, which drive hyperactivation of the PI3K-AKT–mTOR signaling axis, clinically manifesting as epidermal nevi, hemimegalencephaly, and drug-resistant epilepsy (19, 30).